Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343007 | 1.00 | SCN9A (0.46) | SCN9AHTR6ESR1CYP19A1SCN5A | |
| SCHEMBL29979571 | 0.86 | MAPT (0.41) | SCN9AESR1 | |
| SCHEMBL23769056 | 0.86 | MAPT (0.41) | SCN9AESR1 | |
| SCHEMBL29978551 | 0.85 | SCN9A (0.39) | SCN9AHTR6SCN5APSEN1PSEN2 | |
| SCHEMBL30895148 | 0.78 | KDM4E (0.48) | — | |
| SCHEMBL25028039 | 0.78 | KDM4E (0.48) | — | |
| SCHEMBL23768832 | 0.78 | TRPV1 (0.43) | ESR1 | |
| SCHEMBL29978948 | 0.78 | TRPV1 (0.43) | ESR1 | |
| SCHEMBL23769044 | 0.77 | AR (0.42) | SCN9AHTR6ESR1CYP19A1 | |
| SCHEMBL29979459 | 0.77 | AR (0.42) | SCN9AHTR6ESR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | SCN9A 2284/4885HTR6 3635/4885ESR1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.